Choate Investment Advisors Decreases Holdings in Kronos Bio, Inc. (NASDAQ:KRON)

Choate Investment Advisors cut its holdings in shares of Kronos Bio, Inc. (NASDAQ:KRON) by 11.0% during the 4th quarter, HoldingsChannel reports. The fund owned 274,787 shares of the company’s stock after selling 33,910 shares during the quarter. Choate Investment Advisors’ holdings in Kronos Bio were worth $261,000 at the end of the most recent reporting period.

Separately, Deltec Asset Management LLC bought a new position in shares of Kronos Bio in the fourth quarter worth approximately $190,000. Institutional investors own 64.09% of the company’s stock.

Kronos Bio Stock Performance

Shares of Kronos Bio stock opened at $0.95 on Tuesday. Kronos Bio, Inc. has a 52-week low of $0.69 and a 52-week high of $1.60. The stock has a market capitalization of $57.32 million, a price-to-earnings ratio of -0.66 and a beta of 1.79. The company’s 50 day moving average price is $0.98 and its 200-day moving average price is $0.96.

Kronos Bio Profile

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.